Genetic Alliance UK is seeking a new Chief Executive We’re looking for a Chief Executive to deliver our ambitious new strategy and to inspire and lead Genetic Alliance UK’s talented and experienced team following a period of significant change. We are an alliance of over 230 charities and support groups whose collaborative aim is to work together to improve the lives of 3.5 million people in the UK affected by rare or genetic conditions. We run 2 long standing projects, Rare Disease UK and SWAN UK (syndromes without a name). You can find out more about our work at https://ow.ly/eywP50SeetR. We are looking for candidates with a personal or professional passion for driving improvements in the lives of people affected by rare or genetic conditions, who can bring relevant expertise and diverse perspectives to shape our work. You will be a credible senior leader who listens and learns from the views of members, supporters and partners, and builds on the high profile and strong reputation of Genetic Alliance UK. We are seeking to complement the skills of our senior team by recruiting a Chief Executive with expertise in business development and income generation, governance, strategic delivery, impact measurement, operational management, business planning and financial management. It’s a broad role and we’re interested to hear from a range of candidates with different experiences. As Chief Executive at Genetic Alliance UK, you will have the opportunity to work in a cutting-edge environment, developing policy and research and working with leaders across government, science and industry. You will be able to bring positive benefit to countless lives. If you have the drive, energy and relevant experience to lead our organisation towards achieving our ambitions for the genetic rare and undiagnosed community then we would like to hear from you. We want to hear from candidates from all walks of life, and we welcome applications from people with lived experience of rare or genetic conditions either directly or through a family member. People from minority ethnic backgrounds and men are currently under-represented on our staff, and we would welcome applicants who can bring either or both of these perspectives to our work. For an informal conversation about the role, please contact current Chief Executive Louise Fish (louise.fish@geneticalliance.org.uk) and/or Chair Elizabeth Porterfield (chair@geneticalliance.org.uk). Deadline for applications: 17.00 on Monday 1 July 2024 You can find the application pack including a job description and details of how to apply at: https://ow.ly/Wz2r50SeetS. First round interviews will take place by Zoom on Wednesday 10 and Thursday 11 July 2024. We will interview a maximum of 2 final candidates face-to-face in London on Wednesday 17 July 2024.
Genetic Alliance UK’s Post
More Relevant Posts
-
In our latest blog post, we delve into how VSClinical offers a robust and transparent approach to adhering to ACMG guidelines for variant classification. Discover how you can customize frequency thresholds, adjust inheritance modes, and manually select criteria for a more precise and confident genetic interpretation. Whether you're a geneticist, researcher, or healthcare professional, understanding the flexibility of VSClinical can transform your approach to genetic data analysis. Dive into the full article to explore the innovative ways to leverage VSClinical's capabilities: https://bit.ly/3TVob4Z #Genetics #ACMGguidelines #VSClinical #Bioinformatics #GeneticAnalysis
-
Hello everyone, I'm actively looking for a new role in genome analysis, scientific writing, clinical research, clinical data management, project coordinator and would appreciate your support. Thank you in advance for any connections, advice, references or opportunities you can offer #genomeanalyst #variantanalyst #molecularbiology #moleculardiagnostics #genetics #research #lifesciences #NGS #genomesequencing #sequencing #genomics #oncologyclinicalresearch #exome #oncologyresearch #clinicalresearch #clinicaltrials #clinicalresearchassociate #clinicaldatamanagement #projectcoordinator #opentowork
-
Visionary Leader in Genomics and Oncology / Passionate about improving access to life-saving information
After taking a short break from posting, I'm back! This week, let's finish out the last two of the seven ABGC-board-certified practice competencies for Genetic Counselors. Competency #6: Healthcare Systems - demonstrate how disparities, inequities, and systemic bias affect access to healthcare for diverse populations - describe the financial considerations in the delivery of genetic services - advocate for continuity of care - collaborate with members of the Care Team, clients, and other Community Partners (https://lnkd.in/eK_PR4cx) Genetic counselors understand there are barriers to individuals getting the healthcare they may need, whether they are financially based (no insurance or insurance won't cover the needed test or procedure), knowledge-based (the provider isn't aware of their family history and/or the benefit of genetic testing), or socioeconomic imbalances (less is understood about the genetics of minority populations due to biases in research studies). Genetic counselors are tireless ADVOCATES for the patient to get what they need, from start to finish. This is whether they are working 1:1 with the patient in clinic or working to improve access to testing, counseling, or preventative care in the industry. Genetic counselors are excellent COLLABORATORS - due to their skills in communication and counseling. Bottom line - they understand healthcare and the healthcare system, both the provider and the patient point-of-view, and are both leaders and team players. You would do well to add one to your team today. Image by vectorjuice on Freepik
-
-
Join Genetic Technologies’ Exclusive Live Investor Webinar
Join Genetic Technologies’ Exclusive Live Investor Webinar
lifecarenews.in
-
Join Genetic Technologies’ Exclusive Live Investor Webinar
Join Genetic Technologies’ Exclusive Live Investor Webinar
lifecarenews.in
-
What is the story behind the name gMendel® The name gMendel® pays homage to Gregor Mendel, the pioneer of modern genetics. The prefix "g" not only signifies genetics and genomics but also embodies the concepts of "genius" and "genuine," while its form is reminiscent of the DNA double helix, symbolizing the fundamental essence of life. The inception of gMendel® was deeply influenced by the personal journeys of our founders and leadership team, all of whom have been directly affected by rare diseases or genetic disorders through their loved ones. The invaluable time spent with our daughters, sons, siblings, cousins, and close friends has bestowed upon us a profound understanding of the myriad challenges encountered by families navigating the complexities of rare conditions. This experience has also highlighted the often-protracted journey of translating cutting-edge technologies into tangible clinical solutions that can truly benefit the average family. Driven by these personal encounters and a shared vision, our ambition is to revolutionize the diagnosis of genetic disorders and pave the way for the development of more accessible treatments. We are committed to democratizing the diagnostic process, aiming to lift the burden off the shoulders of countless families affected by rare diseases. By bridging the gap between advanced technological research and clinical application, we aspire to make a lasting impact on the lives of individuals living with these challenging conditions. #branding #Innovation #Healthtech #DigitalHealth #healthcare #globalhealth #business #healthinnovation #genetics #genomics #rarediseases #geneticdisorders #genetictesting #screening #diagnostics #artificialintelligence #machinelearning #VC #venturecapital #companiondiagnostics
-
-
Join Genetic Technologies’ Exclusive Live Investor Webinar
Join Genetic Technologies’ Exclusive Live Investor Webinar
lifecarenews.in
-
Excited to announce that FaunaBio and Eli Lilly and Company have announced a strategic collaboration to discover novel #obesity targets using its #Convergence AI platform in a deal worth up to $494M. 🚀🚀🚀 Fauna's Convergence™ AI platform analyzes data collected from the protective adaptations of hibernation biology (and other extreme adaptations) to identify drug targets for humans. Fauna identifies the best genes to target for efficacy in diseases with high unmet need and can identify genes to target within a broad range of treatment modalities. "We are very excited to enter into this collaboration with Lilly, which showcases the power of our Convergence™ AI platform to rapidly identify novel targets for complex disease areas of high unmet need," said Ashley Zehnder, CEO & Co-Founder, Fauna Bio. "Lilly is a leader in obesity treatment, and our approach enables and accelerates discovery across different disease areas and modalities for our partners, who bring deep expertise in drug development." Read the full release: 👇👇👇 https://lnkd.in/eXKDEKze
-
-
The Kenyan Genome Project Embracing Diversity for a Healthier Future! Kenya is home to diverse ethnic groups, each with its own unique heritage. But did you know that our genetic diversity is equally remarkable? Understanding our genetic makeup is a powerful tool for scientific advancements and personalized healthcare. Here at CMB Genomics, we recognize the importance of this and are advocating for the creation of the Kenyan Genome Project (an initiative that aims to sequence the genomes of individuals from all 42 of our diverse ethnic groups). Why is this crucial? 1. Unlocking Insights: This project will allow us to uncover the genetic variations that make us unique. The knowledge can help us understand our susceptibility to diseases, our ability to adapt to our environment, and so much more. 2. Better Healthcare: With this data, healthcare can transition towards a more personalized approach. Physicians can customize treatments according to a patient's unique genetic profile, resulting in treatments that are not only more effective but also less invasive. 3. Preserving Our Heritage: This endeavor serves as a means to safeguard our nation's genetic heritage for generations to come. By contributing to this project, we will leave a lasting legacy of knowledge. 4. Global Collaboration: The Kenyan Genome Project will put us on the global stage of genomic research, fostering collaboration with scientists worldwide. How can you make a difference? 1. Raise Awareness: Share this message and help raise awareness about the vital significance of the Kenyan Genome Project. 2. Support Research: Advocate for research institutions, government agencies, and philanthropic individuals to invest in this groundbreaking initiative. 3. Participate: If you're willing, consider actively taking part in the project. Your involvement has the potential to create a profound impact. Our genetic diversity is not only a treasure but also a source of strength, holding the key to unlocking a healthier future for all Kenyans. #Humangenetics #Africangenomeproject #Kenyangenomeproject #CMBGenomics
-
Wondering how we can improve the classification of genetic variants? A very interesting paper recently published by Moriel Singer-Berk and colleagues in the AJHG proposes an advanced variant classification framework that I believe will help us to better predict the real loss of function variants. #genetics #AJHG #geneticresearch #variantsclassification
Advanced variant classification framework reduces the false positive rate of predicted loss-of-function variants in population sequencing data
cell.com
Chief Executive at Genetic Alliance UK
1moI’m keen to hand the baton on to an inspirimg leader to implement Genetic Alliance UK’s ambitious new strategy and lead our talented and experienced staff on the next stage of this journey. If you would like an informal chat before deciding whether to apply, please get in touch!